CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionP/E ratio is 0.1×, lower than 95% of its Biotechnology peers (median 32.17×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
992.14MUSDvs all stocks (USD)
Trailing P/E
0.1026xvs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.72xvs all stocks
52-Week Change
-54.10%vs all stocks
Market Capitalization
992.14MUSDvs all stocks (USD)
Enterprise Value
632.43MUSDvs all stocks (USD)
Trailing P/E
0.1026xvs Biotechnology peers
Forward P/E
-4.85xvs Biotechnology peers
PEG Ratio
-0.0010xvs Biotechnology peers
Enterprise to EBITDA
-5.39xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.37%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-117.28MUSDvs all stocks (USD)
Net Income (TTM)
627.78MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-140.09MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-79.50MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-371.64MUSDvs all stocks (USD)
Pre-tax Income
-695.98MUSDFY2025 · Dec 31, 2025Net Income
-695.98MUSDFY2025 · Dec 31, 2025EBIT
-371.64MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-34.40MUSDFY2025 · Dec 31, 2025Research & Development
321.53MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
50.11MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.87MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-695.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-158.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-158.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
396.65MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-695.98MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.89MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.91MUSDFY2025 · Dec 31, 2025Other Non-cash Items
518.02MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.41MUSDFY2025 · Dec 31, 2025Capital Expenditures
-142.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-53.66MUSDFY2025 · Dec 31, 2025Sale of Investments
5.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-48.80MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.32MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
326.88MUSDFY2025 · Dec 31, 2025Shares Outstanding
54.46MSharesUpdated Sep 28, 2026Float Shares
37.23MSharesUpdated Sep 28, 2026Shares Short
7.90MSharesUpdated Sep 28, 2026Short Ratio
10.76daysvs all stocks
Short % of Shares Outstanding
15.72%vs all stocks
% Held by Insiders
9.27%vs all stocks
% Held by Institutions
86.80%vs all stocks
Total Cash (MRQ)
466.13MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.88USDUpdated Sep 28, 2026Total Debt (MRQ)
2.88MUSDvs all stocks (USD)
Current Ratio (MRQ)
19.15xvs Biotechnology peers
Book Value per Share (MRQ)
-3.68USDUpdated Sep 28, 2026Total Assets
464.13MUSDvs all stocks (USD)
Total Current Assets
458.11MUSDFY2025 · Dec 31, 2025Total Liabilities
628.44MUSDFY2025 · Dec 31, 2025Total Non-current Assets
6.02MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
603.27MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.17MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
396.49MUSDFY2025 · Dec 31, 2025Other Short-term Investments
58.72MUSDFY2025 · Dec 31, 2025Accounts Payable
5.13MUSDFY2025 · Dec 31, 2025Short-term Debt
280.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
554.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.72MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.15BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-164.31MUSDvs all stocks (USD)
52-Week Low
6.50USDUpdated Sep 28, 202652-Week High
49.95USDUpdated Sep 28, 202652-Week Change
-54.10%vs all stocks
Beta
1.72xvs all stocks
50-Day MA
22.00USDUpdated Sep 28, 2026200-Day MA
16.60USDUpdated Sep 28, 2026Avg 10-Day Volume
1.83MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.08MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
180.58USDUpdated Sep 28, 2026Other Income / Expense
-330.21MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 0.1×, lower than 95% of its Biotechnology peers (median 32.17×)Notable
P/E ratio: 0.10Industry median: 32.17Industry P5: 6.16Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 627,782,016Operating Cash Flow (USD, TTM): -140,087,008
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing Jingyeda Technology Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Beijing Kingee Culture Development Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
China Hi-Tech Group Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated